Funding: the study was supported by the Ministry of Health of the Russian Federation, topic: Pharmaceutical Development and Preclinical Trials of the Peptide Drug for Treatment of Alzheimer's Disease, 125022602911-9.

Acknowledgements: the authors would like to express their gratitude to E.V. Myachin, Chairman of the VSE Cooperative (Moscow, Russia), for providing the HAEE lyophilized synthetic peptide.

Author contribution: Kozin SA — study design, literature review, manuscript writing; Lysikova EA — experimental research involving APP/PS1 mice, проведение transcardial perfusion, histochemical analysis; Yakovlev RYu — analysis of the input HAEE synthetic peptide samples; Mukhina KA, Soloveva АЕ, Shmigol TA — experimental research involving APP/PS1 mice, preparation of brain slices, fluorescence microscopy image acquisition and analysis; Makarov AA, Mitkevich VA — study design, manuscript writing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Engelhardt Institute of Molecular Biology RAS (protocol No. 3 dated 11 September 2025) and conducted in accordance with guidelines for working with laboratory animals.